Indivior
Buying intent
26 tracked signals | Top 15 topics are below | Data and Engineering are carrying most of it.
Attention by team
LinkedIn activity, by teamWhere Indivior's own people are actually spending their attention, by team, by topic. Bands run Low to High against the busiest pairing on this page, and each cell also shows how much of that team's own activity it represents.
Topics being researched
30-day windowEvery tracked topic, ranked by volume, not by our guess at what matters. Confidence is the classifier's own certainty that a signal belongs where we've filed it.
22d ago
12d ago
25d ago
22d ago
11d ago
19d ago
12d ago
20d ago
11d ago
19d ago
16d ago
16d ago
23d ago
19d ago
25d ago
Need intent for a specific topic or industry?
We track the full taxonomy across every account in the graph — including themes not shown on this page.
Who's active at Indivior
verified title on fileTitles, seniority and topic straight from each person's own activity, with a LinkedIn link so you can check any of them yourself.
See everyone, not just the first 10
12 people across every department at Indivior, plus a LinkedIn profile link for each.
Primary products / business lines
LinkedIn company profileIndivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD tr
Top accounts researching Indivior
names withheld on the public pageThese are companies whose own people brought up Indivior unprompted, not accounts we guessed might be interested. We can't yet tell an implementation partner from a genuine buyer here, names unlock along with the buyer profile below.
6,459 companies · 25,813 people are researching Pharmaceutical
Indivior's own team shows 3 signals on this topic. No one outside Indivior has been seen researching the company by name yet — so this is the market it sits in, not a list of its buyers.
- Artificial Intelligence151,426 cos · 839,012 people
- Hiring75,708 cos · 411,263 people
Buyer profile
company size · seniorityCompany size and how senior the people involved are, the two things that decide whether this is a real deal. Competitor overlap isn't computed yet for this account.
Buying committee functions
Employee job titles (LinkedIn)Engineering — 1 person
What's been said
public posts by Indivior's teamNo public post naming Indivior has surfaced in the past year, so this is what Indivior's own team is posting about publicly — their topics, in their words.
Super proud Mom moment! Wow did these years fly! Spending time in Pittsburgh was awesome for me (huge Steelers fan) and Jack is really thriving there- what a great city. An ask for my network please - if anyone is aware of relevant roles (Pittsburgh-based or remote), I would appreciate any and all insights or referrals. Thanks all.
May 2026📣I’m looking for someone who thrives in a performance driven, culture•Brings strong clinical and sales acumen•Is passionate about educating providers and staff• Can execute strategically while building trusted customer relationships• Wants to be part of a high-performing, patient-focused team!
May 2026We didn't launch Blueprint Health Strategies Group with a post. We launched it with a client. So now that we've come up for air, here's an introduction. I founded Blueprint Health Strategies Group alongside my partners, Matthew "Matt" R Ruth and Jonathan Bloomfield , to close a gap we kept running into throughout our careers: companies with strong science and real potential, stuck between strategy and execution. Rare disease. Complex products. Markets where the standard playbook doesn't apply and access is anything but straightforward. BHSG exists to be the team that actually gets in and does the work. Commercial buildouts, market access strategy, rare disease go-to-market, expert network activation, and transaction support. We work alongside our clients' leadership, not above it. Over the last six months we've been coast to coast, in the rooms and at the tables that matter. That's what this looks like in practice: early, relationship-driven, and present when it counts. If you're navigating a commercialization challenge, a market access question, or a rare disease launch and you need people who've genuinely done it, I'd love to connect. #BlueprintHSG #RareDisease #MarketAccess #HealthcareCommercial #CommercialStrategy
May 2026Exciting progress! Congrats to team Frenelle. Completing PK/tox for FRN01 is a meaningful milestone for patients with OUD who desperately need better treatment options. The hub-and-spoke model looks like a smart way to drive capital-efficient innovation across multiple programs. Looking forward to watching this one continue to develop.
May 2026Strategic priorities
Earnings call; SEC filingsCustomer Relationship Management (CRM); Paid Search; Cash Flow
What changed recently
Earnings call; SEC filingsCustomer Relationship Management (CRM); Paid Search; Cash Flow